BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Abramo A, Vita S, Maffongelli G, Mariano A, Agrati C, Castilletti C, Goletti D, Ippolito G, Nicastri E; Spallanzani COVID-19 Case Investigation Team. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. Int J Infect Dis 2021;107:247-50. [PMID: 33901654 DOI: 10.1016/j.ijid.2021.04.068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Dominelli F, Zingaropoli MA, Tartaglia M, Tortellini E, Guardiani M, Perri V, Pasculli P, Ciccone F, Malimpensa L, Baione V, Napoli A, Gaeta A, Lichtner M, Conte A, Mastroianni CM, Ciardi MR. Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1050183] [Reference Citation Analysis]
2 Madariaga-Mazón A, Naveja JJ, Becerra A, Alberto Campillo-Balderas J, Hernández-Morales R, Jácome R, Lazcano A, Martinez-Mayorga K. Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity. Comput Struct Biotechnol J 2022;20:5181-92. [PMID: 36097553 DOI: 10.1016/j.csbj.2022.08.056] [Reference Citation Analysis]
3 Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Koblischke M, Hommer N, Wagner A, Mayer M, Schubert L, Hartl L, Kozbial K, Hofer P, Kartnig F, Hummel T, Kerschbaumer A, Deimel T, Puchner A, Gudipati V, Thalhammer R, Munda P, Uyanik-Ünal K, Zuckermann A, Novacek G, Reiberger T, Garner-Spitzer E, Reindl-Schwaighofer R, Kain R, Winkler S, Smolen JS, Stiasny K, Fischer GF, Perkmann T, Haslacher H, Zeitlinger M, Wiedermann U, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun 2022;13:5362. [PMID: 36097029 DOI: 10.1038/s41467-022-33036-y] [Reference Citation Analysis]
4 Yalcin Mutlu M, Taubmann J, Wacker J, Tascilar K, Fagni F, Gerner M, Klett D, Schett G, Manger B, Simon D. Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis—A case report and literature review. Front Med 2022;9. [DOI: 10.3389/fmed.2022.934169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Spinicci M, Mazzoni A, Coppi M, Antonelli A, Salvati L, Maggi L, Basile G, Graziani L, Di Lauria N, Di Pilato V, Kiros ST, Beccastrini E, Saccardi R, Angileri M, Cecchi M, Cusi MG, Rossolini GM, Annunziato F, Bartoloni A, Parronchi P. Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications. J Clin Immunol 2022. [PMID: 35779200 DOI: 10.1007/s10875-022-01313-6] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 D'Abramo A, Vita S, Maffongelli G, Beccacece A, Agrati C, Cimini E, Colavita F, Giancola ML, Cavasio A, Nicastri E; Spallanzani COVID-19 Case Investigation Team. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. Front Immunol 2022;13:911339. [PMID: 35711444 DOI: 10.3389/fimmu.2022.911339] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Petrone L, Tortorella C, Aiello A, Farroni C, Ruggieri S, Castilletti C, Meschi S, Cuzzi G, Vanini V, Palmieri F, Prosperini L, Haggiag S, Galgani S, Grifoni A, Sette A, Gasperini C, Nicastri E, Goletti D. Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. Front Neurol 2022;13:881988. [PMID: 35711277 DOI: 10.3389/fneur.2022.881988] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Dioverti MV, Gaston DC, Morris CP, Huff CA, Jain T, Jones R, Anders V, Lederman H, Saunders J, Mostafa HH, Avery RK. Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients. Open Forum Infect Dis 2022;9:ofac064. [PMID: 35663288 DOI: 10.1093/ofid/ofac064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Totschnig D, Doberer D, Haberl R, Wenisch C, Valipour A. Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab. IDCases 2022. [DOI: 10.1016/j.idcr.2022.e01528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C, Meylan S, Mehra V, Styczynski J, Marchesi F, Besson C, Baldanti F, Masculano RC, Beutel G, Einsele H, Azoulay E, Maertens J, de la Camara R, Pagano L; ECIL 9. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia 2022. [PMID: 35488021 DOI: 10.1038/s41375-022-01578-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
11 Schiavetti I, Ponzano M, Signori A, Bovis F, Carmisciano L, Sormani MP. Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis. Mult Scler Relat Disord 2022;57:103358. [PMID: 35158467 DOI: 10.1016/j.msard.2021.103358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
12 Meyerowitz EA, Richterman A. SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. Infectious Disease Clinics of North America 2022. [DOI: 10.1016/j.idc.2022.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ocrelizumab/rituximab. Reactions Weekly 2021;1869:293-293. [DOI: 10.1007/s40278-021-01158-z] [Reference Citation Analysis]